Precision oncology has, for most of its history, been anchored around a single decision point: a tumor biopsy or blood based genomic test performed near diagnosis, used to identify a specific mutation or biomarker that determines which targeted therapy a patient should receive. That single point-in-time model is giving way to a more continuous approach, as circulating tumor DNA testing, commonly known as liquid biopsy, has matured to the point where oncologists are increasingly using it not just to select an initial therapy but to monitor treatment response over time and, in a growing number of cases, to detect signs of cancer recurrence months before it would become visible on standard imaging.
The technology underlying this shift relies on detecting small fragments of tumor derived DNA circulating in a patient's blood, fragments that are shed by cancer cells and can be detected and sequenced from a simple blood draw rather than requiring an invasive tissue biopsy. Sensitivity and specificity of these assays have improved substantially over the past several years, driven by advances in sequencing technology and by the accumulation of large clinical validation datasets across multiple cancer types, to the point where several liquid biopsy based monitoring tests have now received regulatory clearance specifically for tracking minimal residual disease after initial cancer treatment.
Why minimal residual disease monitoring changes clinical practice
Minimal residual disease testing addresses a problem that has long troubled oncologists managing patients after surgery or initial systemic therapy: distinguishing patients who are genuinely cancer free from those who harbor microscopic residual disease too small to detect on any imaging study but large enough to eventually cause recurrence. Historically, oncologists have had to make decisions about additional adjuvant therapy, meaning treatment given after the primary treatment to reduce recurrence risk, based on statistical risk factors derived from large population studies rather than direct evidence of whether a specific individual patient still harbors detectable disease.
Liquid biopsy based minimal residual disease testing offers, for the first time at meaningful clinical scale, a way to make that determination on an individual patient basis, detecting circulating tumor DNA that indicates residual cancer cells remain even when a patient appears clinically cancer free by every other available measure. Detecting this molecular evidence months before a recurrence would become apparent on imaging gives oncologists a meaningfully earlier window to intervene with additional therapy, potentially improving outcomes for patients who would otherwise not have their recurrence identified and treated until it had progressed further.
The evidence base is still being built carefully
It is important for clinicians and patients to understand the current limits of this technology alongside its promise. While detecting circulating tumor DNA reliably predicts a higher risk of eventual clinical recurrence across the cancer types where it has been most extensively studied, the clinical trials needed to prove that acting on a positive test result with earlier additional treatment actually improves survival outcomes, rather than simply providing earlier information, are still underway in many cancer types. This distinction matters considerably, since detecting molecular evidence of disease earlier is only clinically valuable if there is an effective intervention available to act on that information, and if that intervention genuinely changes the ultimate outcome for the patient rather than simply moving the timing of treatment earlier without improving survival.
What this means for oncology care delivery and diagnostics companies
For oncology practices and health systems, the expansion of liquid biopsy from a one time diagnostic test into an ongoing monitoring tool changes both clinical workflow and cost considerations. Serial blood draws for monitoring purposes, potentially repeated every few months over years of post treatment surveillance, represent a different care delivery model and a different reimbursement conversation than the single test historically used at diagnosis, and payers are still working through coverage policy for many of these monitoring applications as the supporting clinical evidence continues to accumulate across different cancer types.
For diagnostics companies operating in this space, the shift toward monitoring applications represents a considerably larger addressable market opportunity than diagnostic testing alone, since a single patient may require dozens of monitoring tests over the years following initial cancer treatment rather than the one or two tests typically used for initial treatment selection. This has intensified competitive activity among liquid biopsy companies to expand their validated use cases into monitoring applications across additional cancer types, generate the clinical trial evidence needed to support both regulatory clearance and payer coverage, and build the assay sensitivity needed to reliably detect the very low levels of circulating tumor DNA present in patients with minimal residual disease.
Key Signals
Circulating tumor DNA testing is expanding from a one time diagnostic tool used at initial treatment selection into an ongoing monitoring technology capable of detecting minimal residual disease and recurrence months before standard imaging would show it. This shift gives oncologists individualized evidence about residual cancer risk for the first time at meaningful scale, replacing decisions previously based only on population level statistical risk factors. Clinical trials proving that acting on earlier molecular detection actually improves survival outcomes, rather than only providing earlier information, remain incomplete for many cancer types, a distinction that should temper enthusiasm until that evidence matures. The shift toward repeated monitoring testing represents a substantially larger addressable market for diagnostics companies than one time testing, intensifying competition to expand validated use cases and build payer coverage across additional cancer types.
